MEDP:NGS-Medpace Holdings Inc. (USD)

EQUITY | Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 395.93

Change

0.00 (0.00)%

Market Cap

USD 1.47B

Volume

0.14M

Analyst Target

USD 118.40
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Medpace Holdings Inc is a clinical contract research organisation. It is engaged in providing scientifically-driven clinical research-based drug and medical device development services to the biotechnology, pharmaceutical and medical device industries.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-28 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

+27.42 (+5.26%)

USD 43.04B
ICLR ICON PLC

+6.23 (+1.97%)

USD 26.09B
ILMN Illumina Inc

-0.57 (-0.49%)

USD 18.41B
NTRA Natera Inc

+1.79 (+1.70%)

USD 12.93B
EXAS EXACT Sciences Corporation

-0.66 (-1.22%)

USD 9.96B
RDNT RadNet Inc

+1.51 (+2.66%)

USD 4.19B
SHC Sotera Health Co

+0.01 (+0.09%)

USD 3.13B
OLK Olink Holding AB ADR

+0.29 (+1.22%)

USD 2.90B
GH Guardant Health Inc

+1.02 (+4.12%)

USD 2.74B
NEOG Neogen Corporation

+0.21 (+1.60%)

USD 2.67B

ETFs Containing MEDP

UIQI:F UBS (Irl) Fund Solutions .. 96.30 % 0.00 %

+1.22 (+2.14%)

USD 0.31B
UIQI:XETRA UBSs plc - MSCI AC Asia E.. 96.30 % 0.00 %

+1.02 (+2.14%)

USD 0.31B
AJEUAS:SW UBS (Irl) Fund Solutions .. 96.30 % 0.00 %

+2.46 (+2.14%)

N/A
LCPE:LSE Ossiam Shiller Barclays C.. 7.75 % 0.00 %

+350.00 (+2.14%)

USD 0.17B
DXSH:XETRA Xtrackers - Stoxx Europe .. 4.82 % 0.00 %

+0.82 (+2.14%)

USD 0.03B
L6EW:LSE Ossiam Stoxx Europe 600 E.. 4.65 % 0.00 %

+71.00 (+2.14%)

USD 0.12B
S6EW:LSE Ossiam Stoxx Europe 600 E.. 4.65 % 0.00 %

+1.06 (+2.14%)

USD 0.12B
S6EW:PA Ossiam Stoxx Europe 600 E.. 4.65 % 0.00 %

+0.98 (+2.14%)

USD 0.12B
OSX6:F Ossiam Lux - Ossiam Stoxx.. 4.65 % 0.00 %

+1.00 (+2.14%)

USD 0.12B
OSX6:XETRA Ossiam Stoxx Europe 600 E.. 4.65 % 0.00 %

+0.88 (+2.14%)

USD 0.16B
S6EW:SW Ossiam STOXX® Europe 600.. 4.65 % 0.00 %

N/A

USD 0.12B
FCII:CA Franklin ClearBridge Sust.. 4.54 % 0.00 %

+0.35 (+2.14%)

CAD 0.02B
PTH Invesco DWA Healthcare Mo.. 4.31 % 0.60 %

+0.76 (+2.14%)

USD 0.14B
AMID Argent Mid Cap ETF 3.54 % 0.00 %

+0.41 (+2.14%)

USD 0.06B
XCLN:CA iShares Global Clean Ener.. 3.46 % 0.00 %

+0.55 (+2.14%)

CAD 7.86M
IQQH:F iShares Global Clean Ener.. 3.45 % 0.00 %

+0.10 (+2.14%)

USD 3.08B
IQQH:XETRA iShares Global Clean Ener.. 3.45 % 0.00 %

+0.10 (+2.14%)

USD 3.34B
INRG:SW iShares Global Clean Ener.. 3.45 % 0.00 %

+0.12 (+2.14%)

USD 3.09B
JSMD Janus Henderson Small/Mid.. 2.92 % 0.50 %

+0.85 (+2.14%)

USD 0.36B
STUX:SW SPDR® MSCI Europe Utilit.. 2.91 % 0.00 %

+3.54 (+2.14%)

USD 0.12B
UTIL:LSE SPDR® MSCI Europe Utilit.. 2.85 % 0.00 %

+2.87 (+2.14%)

USD 0.12B
STU:PA SPDR® MSCI Europe Utilit.. 2.85 % 0.00 %

+2.82 (+2.14%)

USD 0.12B
SPYU:F SSgA SPDR ETFs Europe II .. 2.85 % 0.00 %

+3.10 (+2.14%)

USD 0.12B
SPYU:XETRA SPDR® MSCI Europe Utilit.. 2.85 % 0.00 %

+2.70 (+2.14%)

USD 0.16B
ZCLN:CA BMO Clean Energy Index ET.. 2.63 % 0.00 %

+0.19 (+2.14%)

CAD 0.07B
INRG:LSE iShares Global Clean Ener.. 2.62 % 0.00 %

+4.75 (+2.14%)

USD 3.00B
INRE:PA iShares Global Clean Ener.. 2.62 % 0.00 %

+0.16 (+2.14%)

N/A
FXH First Trust Health Care A.. 2.16 % 0.63 %

+1.26 (+2.14%)

USD 1.25B
FHH:CA First Trust AlphaDEX US H.. 2.13 % 0.77 %

N/A

CAD 0.01B
FHH-F:CA First Trust AlphaDEX U.S... 2.13 % 0.00 %

N/A

CAD 0.01B
DRDR:LSE iShares Healthcare Innova.. 1.79 % 0.00 %

+6.25 (+2.14%)

USD 1.07B
2B78:XETRA iShares Healthcare Innova.. 1.76 % 0.00 %

+0.09 (+2.14%)

USD 1.14B
HEAL:LSE iShares Healthcare Innova.. 1.72 % 0.00 %

+0.14 (+2.14%)

USD 1.07B
HEAL:SW iShares Healthcare Innova.. 1.72 % 0.00 %

+0.04 (+2.14%)

N/A
QSML:AU VanEck MSCI International.. 1.22 % 0.00 %

+0.07 (+2.14%)

USD 0.57B
PSC Principal U.S. Small-Cap .. 0.00 % 0.38 %

+0.55 (+2.14%)

USD 0.53B
XMHQ Invesco S&P MidCap Qualit.. 0.00 % 0.25 %

+1.35 (+2.14%)

USD 4.66B
JELS:LSE 0.00 % 0.00 %

N/A

N/A
IBBJ 0.00 % 0.00 %

N/A

N/A
2B78:F iShares Healthcare Innova.. 0.00 % 0.00 %

+0.10 (+2.14%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 29.17% 91% A- 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.17% 91% A- 87% B+
Trailing 12 Months  
Capital Gain 97.83% 93% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 97.83% 93% A 94% A
Trailing 5 Years  
Capital Gain 604.88% 100% F 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 604.88% 100% F 97% N/A
Average Annual (5 Year Horizon)  
Capital Gain 44.26% 82% B 89% A-
Dividend Return 44.26% 82% B 89% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 38.82% 66% D+ 46% F
Risk Adjusted Return 114.01% 100% F 99% N/A
Market Capitalization 1.47B 94% A 94% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 128.40 38% 24%
Price/Book Ratio 21.90 6% 5%
Price / Cash Flow Ratio 28.31 12% 9%
Price/Free Cash Flow Ratio 33.42 6% 7%
Management Effectiveness  
Return on Equity 61.35% 98% 98%
Return on Invested Capital 57.06% 100% 96%
Return on Assets 13.89% 98% 98%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.